contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


ascelia-pharma-wrap-up-from-interview-deputy-ceo-and-cfo-julie-waras-brogren

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

Ascelia Pharma är ett läkemedelsbolag. Bolaget är specialiserat på utveckling av särläkemedel inom onkologi (cancer). Bolaget utvecklar diverse läkemedelskandidater, där störst användning återfinns inom behandling av cancer som drabbat lever och magsäck. Bolaget grundades år 2000 och har huvudkontor i Malmö, Sverige, men är verksamt på en global marknad.

Ascelia Pharma

Wrap up from interview Deputy CEO and CFO Julie Waras Brogren

The Share Price Closed Up by 5,6% in SEK 3,02 Friday.
We hosted an event with Deputy CEO and CFO Julie W. Brogren in connection with the company&#x2019;s full-year report. The focus of the event was a review of the financial results, key developments from 2024, and what investors should pay attention to in 2025.
Deputy CEO and CFO Julie W. Brogren presented the Phase 3 data from the SPARKLE study on Orviglance, highlighting the primary and secondary endpoints as well as the safety profile:
<ul style="margin-top: 0cm" type="disc">
<li class="MsoNormal" style="mso-list: l0 level1 lfo1; tab-stops: list 36.0pt">&#x201c;The Phase 3 study demonstrated strong superiority in the visualization of focal liver lesions with Orviglance (CMRI) compared to unenhanced MRI. Visualization scores were significantly higher with Orviglance across all three readers, achieving statistical significance.</li>
<li class="MsoNormal" style="mso-list: l0 level1 lfo1; tab-stops: list 36.0pt">Secondary efficacy endpoints supported the primary analysis, confirming the robustness of the positive results, including lesion detection. Across all readers, at least one new lesion was detected in 40&#x2013;52% of patients with Orviglance.</li>
<li class="MsoNormal" style="mso-list: l0 level1 lfo1; tab-stops: list 36.0pt">In terms of common adverse events, they were consistent with previous studies, such as mild to moderate nausea, and no serious adverse drug reactions were observed.&#x201d;</li>
</ul>
The study was conducted on 286 healthy individuals, demonstrating convincing efficacy and a strong safety profile for the target patient population.
The company&#x2019;s current focus is on the next meeting with the FDA, scheduled for Q1 2025. During the event, Deputy CEO and CFO Julie W. Brogren elaborated on the process, noting that the meeting will cover both technical and strategic aspects. The company maintains its previous guidance, expecting to provide more information in Q1 2025. Additionally, she provided insights into the approval timeline and potential pathways with the FDA.
Another key topic was the timing of a potential partnership agreement for Orviglance. There has been ongoing speculation about when such an agreement might be finalized. Julie W. Brogren shared insights into what the company is looking for in a partner and confirmed that time is on their side. With strong headline data, a comprehensive study data package, secured financing to late 2025, and significant efforts invested in preparing for the FDA meeting, Ascelia Pharma is well-positioned for the next steps.
If you missed Friday&#x2019;s event, you can watch it here: <a href="https://youtu.be/NF5LAX9zKCM" target="_blank" rel="noopener">Ascelia Pharma interview</a>
Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility agreement. Claus Thestrup, 8:15 AM, 10-02-2025